Eporon

Eporon

epoetin alfa

Manufacturer:

Dong-A Pharm

Distributor:

F.C.P.
Concise Prescribing Info
Contents
Recombinant human erythropoietin α
Indications/Uses
Anemia associated w/ chronic renal failure including patients on dialysis (end-stage renal disease) & patients not on dialysis.
Dosage/Direction for Use
50 IU/kg IV 3 times/wk. Adjust dose & frequency depending on patient's response in increments of 25 IU/kg/wk IV at 4-wk intervals. If Hb increases >2 g/dL/wk, reduce treatment to 2 times/wk.
Contraindications
Hypersensitivity to mammalian cell-derived products or human albumin. History of pure red cell aplasia after treatment of erythropoietin, uncontrolled HTN.
Special Precautions
History of seizure disorder or underlying hematologic disease (eg, sickle cell anemia, myelodysplastic syndromes or hypercoagulable disorders). Porphyria. Evaluate Fe status including transferrin saturation & serum ferritin. Monitor renal function, fluid & electrolyte balance, hematocrit & BP. Perform CBC w/ differential & platelet count regularly. Pregnancy & lactation.
Adverse Reactions
HTN, thrombotic/vascular events, edema, DVT, fever, dizziness, insomnia, headache, pruritus, skin pain, rash, nausea, constipation, vomiting, diarrhea, dyspepsia.
ATC Classification
B03XA01 - erythropoietin ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.
Presentation/Packing
Form
Eporon inj (vial) 4000 IU
Packing/Price
(pre-filled syringe) 10 × 1's; (vial) 1's;10 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in